CLOVER HEALTH INVESTMENTS, CORP. /DE
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $CLOV in the last 7 days.
Clover Health (CLOV) received top Medicare Advantage ratings in NJ, GA, and SC for 2027, with high scores for care continuity and a 4.82/5 HEDIS score, according to U.S. News. The company has ranked #1 among non-SNP PPO plans with over 2,000 members for three consecutive years.
Clover Health (CLOV) filed an 8-K with the SEC on October 9, 2026, reporting corporate changes and voting matters. The filing includes exhibits and is related to previous filings. No specific financial data or significant changes were mentioned in the summary.
Clover Health Investments (CLOV) reported that nearly half of its Medicare Advantage members joined in 2025 or 2026, impacting short-term profits. Membership grew 48% YoY to 157,000, with new members accounting for 49%. Despite a 70% stock return over 12 months, CLOV's revenue declined 0.7%, and gross profit grew slower than revenue. Management raised full-year guidance but cautioned about future trends.
Recent CLOV coverage spans financial news, corporate actions and market movers.
In the last 30 days, CLOV insiders filed 10 SEC Form 4 transactions — no purchases and 10 sales ($2.1M). The most active reporter was Reynoso Jamie L., CEO, Medicare Advantage, with 4 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Positive rating may lift investor sentiment and support modest share price appreciation.
The filing introduces uncertainty about upcoming corporate actions, likely prompting modest short‑term pressure.
Guidance upgrade suggests higher future earnings.
Higher CMS star ratings should support Clover’s Medicare Advantage competitiveness and year-round PPO enrollment, but the rating’s appeal-related exclusions add uncertainty.
Positive reaction relative to peers.
AlphAI scores every news story that mentions CLOV with an AI model for sentiment and relevance, and aggregates insider trades from CLOVER HEALTH INVESTMENTS, CORP. /DE's SEC EDGAR Form 4 filings. Figures refresh continuously.
Clover Health (CLOV) received top Medicare Advantage ratings in NJ, GA, and SC for 2027, with high scores for care continuity and a 4.82/5 HEDIS score, according to U.S. News. The company has ranked #1 among non-SNP PPO plans with over 2,000 members for three consecutive years.
1 min readClover Health (CLOV) filed an 8-K with the SEC on October 9, 2026, reporting corporate changes and voting matters. The filing includes exhibits and is related to previous filings. No specific financial data or significant changes were mentioned in the summary.
1 min readClover Health Investments (CLOV) reported that nearly half of its Medicare Advantage members joined in 2025 or 2026, impacting short-term profits. Membership grew 48% YoY to 157,000, with new members accounting for 49%. Despite a 70% stock return over 12 months, CLOV's revenue declined 0.7%, and gross profit grew slower than revenue. Management raised full-year guidance but cautioned about future trends.
2 min readClover Health (CLOV) announced CMS awarded its Medicare Advantage PPO plans 5 Stars and HMO plan 4.5 Stars for 2027, impacting 2028 payments. 5-Star rating allows year-round PPO enrollment, though CMS noted the PPO rating excludes 20 measures due to a court decision under appeal.
3 min readAT&T (T), Verizon (VZ), and T-Mobile (TMUS) fell 7-8% after SpaceX (SPCX) acquired 800 MHz spectrum, enabling Starlink Mobile to compete with traditional carriers. SpaceX shares rose 1%. Humana (HUM) surged 16% on improved Medicare Advantage Star ratings. CVS (CVS) and Alignment (ALHC) dropped 4% and 21% respectively on CMS rating downgrades. American Express (AXP) fell 1% after a $350M penalty for compliance failures.
2 min readToy Andrew (Chief Executive Officer) sold 318,806 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $4.19 ($1.34M total) on 2026-10-01 under a Rule 10b5-1 trading plan.
1 min readClover Health (CLOV) announced its 2027 Medicare Advantage plans, emphasizing PPO choice, preventive care, and member value. The plans feature low premiums, no referrals, and benefits like routine dental and vision. Clover Assistant, the company's technology, supports physicians in identifying care needs. The plans will be available to 5.2 million Medicare-eligible beneficiaries across 203 counties in five states.
2 min readClover Health Investments (CLOV) added former U.S. Senator Robert G. Torricelli and MedPAC Commissioner Dr. Brian J. Miller to its Board of Directors, expanding it to nine members. Torricelli and Miller bring policy and clinical expertise, respectively, to support CLOV's Medicare Advantage strategy and cost-saving initiatives, according to the company.
1 min readCLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 Clover Health Welcomes Former U.S. Senator Robert Torricelli and MedPAC Commissioner Dr. Brian J. Miller M.D. to Its Board of Directors WILMINGTON, Del., September 24, 2026 — Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”)
1 min readClover Health's former officer, Brady Priest, plans to sell 141,418 shares, valued at $631,162.68, according to a regulatory filing. Priest also reported four prior sales totaling 1,205,209 shares between August 7 and September 15, 2026, with proceeds ranging from $305,113.45 to $2,171,597.33.
1 min read
